AGMB (AgomAb Therapeutics NV) EV-to-FCF: (As of Jul. 12, 2026)


AGMB AgomAb Therapeutics NV AGMB
14 GF Score
Price $13.08
! 1 Warning Sign
View Full Analysis

What is AgomAb Therapeutics NV EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, AgomAb Therapeutics NV's Enterprise Value is $509.23 Mil. AgomAb Therapeutics NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil. Therefore, AgomAb Therapeutics NV's EV-to-FCF for today is .

The historical rank and industry rank for AgomAb Therapeutics NV's EV-to-FCF or its related term are showing as below:

AGMB' s EV-to-FCF Range Over the Past 10 Years
Min: -8.4   Med: 0   Max: 0
Current: -8.4
AGMB's EV-to-FCF is ranked worse than
100% of 329 companies
in the Biotechnology industry
Industry Median: 15.85 vs AGMB: -8.40

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-07-12), AgomAb Therapeutics NV's stock price is $13.08. AgomAb Therapeutics NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.418. Therefore, AgomAb Therapeutics NV's PE Ratio (TTM) for today is At Loss.

AgomAb Therapeutics NV  (NAS:AGMB) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

AgomAb Therapeutics NV's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=13.08/-0.418
=At Loss

AgomAb Therapeutics NV's share price for today is $13.08.
AgomAb Therapeutics NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.418.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

AgomAb Therapeutics NV EV-to-FCF Related Terms

AgomAb Therapeutics NV EV-to-FCF Historical Data

* Premium members only.

The historical data trend for AgomAb Therapeutics NV's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AgomAb Therapeutics NV EV-to-FCF Chart

AgomAb Therapeutics NV Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EV-to-FCF
0.00 0.00 0.00 0.00 0.00

AgomAb Therapeutics NV Quarterly Data
Dec21 Dec22 Dec23 Dec24 Sep25 Dec25
EV-to-FCF Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

AGMB vs DNA, ACRS, RLMD: EV-to-FCF Comparison

For the Biotechnology subindustry, AgomAb Therapeutics NV's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AgomAb Therapeutics NV EV-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AgomAb Therapeutics NV's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where AgomAb Therapeutics NV's EV-to-FCF falls into.


AGMB
14GF Score
AgomAb Therapeutics NV AGMB
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AgomAb Therapeutics NV EV-to-FCF Calculation

AgomAb Therapeutics NV's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=509.226/0
=

AgomAb Therapeutics NV's current Enterprise Value is $509.23 Mil.
AgomAb Therapeutics NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AgomAb Therapeutics NV Business Description

Address 1/6 Posthoflei, Antwerp, BEL, 2600
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score

Get the complete analysis for AGMB

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.08
Price